516.36MMarket Cap-4.62P/E (TTM)
7.380High7.130Low2.73MVolume7.180Open7.110Pre Close19.77MTurnover3.87%Turnover RatioLossP/E (Static)71.12MShares14.84052wk High3.87P/B512.53MFloat Cap5.27552wk Low--Dividend TTM70.60MShs Float978.000Historical High--Div YieldTTM3.52%Amplitude-1731.000Historical Low7.243Avg Price1Lot Size
Altimmune Stock Forum
$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Will a partner be announced or are the rumours true a buy out is eminent..!
No comment yet